Evidence map›Paper›PMID 28606464›Full record

ArticleEuropean journal of cancer (Oxford, England : 1990)2017

Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44].

Christophe Massard, Kim Nguyen Chi, Daniel Castellano, Johann de Bono, Gwenaelle Gravis, Luc Dirix, Jean-Pascal Machiels, Alain Mita, Begoña Mellado, Sabine Turri and 4 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in European journal of cancer (Oxford, England : 1990), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Christophe MassardDrug Development Department, Gustave Roussy, University of Paris Sud, Villejuif, France; Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: christophe.massard@gustaveroussy.fr.
Kim Nguyen ChiBC Cancer Agency, Vancouver, Canada.
Daniel CastellanoUniversity Hospital 12 de Octubre, CIBER-ONC, Madrid, Spain.
Johann de BonoInstitute of Cancer Research, London, UK.
Gwenaelle GravisInstitut Paoli-Calmettes, Marseille, France.
Luc DirixSt. Augustinus Hospital, Antwerp, Belgium.
Jean-Pascal MachielsInstitut Roi Albert II, Service d'Oncologie Médicale, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Universitécatholique de Louvain, Brussels, Belgium.
Alain MitaCedars-Sinai Medical Center, Los Angeles, CA, USA.
Begoña MelladoMedical Oncology Department, Hospital Clínic, IDIBAPS, Barcelona, Spain.
Sabine TurriNovartis Pharma S.A.S, Rueil-Malmaison, France.
Joan MaierNovartis Pharma AG, Basel, Switzerland.
Denes CsonkaNovartis Pharma AG, Basel, Switzerland.
Arunava ChakravarttyNovartis Healthcare Pvt. Ltd., Hyderabad, India.
Karim FizaziDepartment of Cancer Medicine, Gustave Roussy, University of Paris Sud, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID28606464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.